Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich - Goldman Sachs Leszek Sulewski - Truist Securities David Amsel ...

Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒ ‒ Af irming 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, May 3, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today f ...

Amneal Pharmaceuticals (AMRX) shares rallied 12% in the last trading session to close at $6.05. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.7% loss over the past four weeks.The sudden soaring of the stock was observed after Amneal announced the commercial launch of over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg in the United States, following its FDA approval, to help ...

Amneal Pharmaceuticals (AMRX) shares rallied 7.3% in the last trading session to close at $6.34. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.2% gain over the past four weeks.The rise in share price is attributable to positive investor expectations for the company’s prospects. Amneal is involved in the development, marketing, and distribution of a diverse portfolio of over 270 pharmaceutical products, in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or oth ...

Amneal Pharmaceuticals, Inc. AMRX) Q4 2023 Earnings Conference Call March 1, 2024 8:30 AM ET Company Participants Chirag Patel - Co-Founder & Co-CEO Chintu Patel - Co-Founder & Co-CEO Tasos Konidaris - CFO Andy Boyer - Generics Joe Renda - SVP & CCO, Specialty Harsher Singh - SVP, Biosciences Jason Daly - Chief Legal Officer Tony DiMeo - IR Conference Call Participants Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Balaji Prasad - Barclays Chris Schott - J.P. Morgan Leszek Sulewski - Truist Secu ...

Amneal Pharmaceuticals (AMRX) reported $616.98 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 1.2%. EPS of $0.14 for the same period compares to $0.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $630.67 million, representing a surprise of -2.17%. The company delivered an EPS surprise of +100.00%, with the consensus EPS estimate being $0.07.While investors scrutinize revenue and earnings changes year-over-year and how they com ...

Q4 2023 Earnings Call March 1, 2024 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; ex ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.12 per share when it actually produced earnings of $0.19, delivering a surprise of 58.33%.Over the last four qu ...

Exhibit 99.1 1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income of $44 million, Adjusted EBITDA of $142 million; Adjusted Diluted EPS of $0.14 ‒ (1) (1) (1) ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Ad ...